relative to other specialties. There was no significant difference between the procedure, the cause for litigation or the defendant specialty, and the outcome of the lawsuit or the final monetary award.
PURPOSE:
From surgery length and postoperative activity restrictions alone, free tissue transfer (FTT)-based breast reconstruction patients have en elevated risk of developing postoperative venous thromboembolism based on their Caprini score. 1 However, because microanastomotic patency is critical, microsurgeons are keen on minimizing thrombophilic and vasoactive conditions. Additionally, compliance with traditional subcutaneous-based prophylaxis regimens is poor. 2 Consequently, traditional dogma regarding appropriate FTT thrombophylaxis remains split and conclusive evidence is lacking. The purpose of this study was to examine the antithrombotic utility of factor Xa inhibitors after FTT.
METHODS:
A single-surgeon, single-institution retrospective review was performed from January 2016 to January 2019 of patients undergoing FTT who received postoperative prophylactic anticoagulation with subcutaneous lovenox during their hospital stay and then postoperatively with an oral factor Xa inhibitor: rivaroxaban 10 mg daily for 10-14 days. Patients also received aspirin 81 mg for 30 days postoperatively. Preoperative hematology testing to identify thrombophilias was performed, and these patients received intravenous heparin 500 units/h for 5 days postoperatively, followed by Xarelto or home anticoagulation. The frequencies of postoperative deep venous thrombosis/venous thromboembolism (VTE) and outpatient hematoma were compared between patients with diagnosed thrombophilia and those without known risk factors.
RESULTS:
One hundred sixty-three FTTs performed in 105 patients were included. The average follow-up was 11 months. No patient developed postoperative deep venous thrombosis, VTE, or outpatient hematoma. Postoperatively, 99.3% (162/163) of patients received rivaroxaban and 1.2% (2/163) remained on home (preoperative) apixaban regiments. Flap success (98.8%; 161/163) was achieved. Patients (3.7%; n = 6) were affected by thrombophilia: plasminogen-activator inhibitor-1 (n = 1), malignancy (n = 2), hyperhomocysteinemia (n = 1), factor II deficiency (n = 1), or severe lower extremity trauma (n = 1). Reoperation on postoperative day 1-2 was required in 3% (5/163) of flaps for hematoma evacuation (4) and microanastomotic venous congestion (1) . Eighty percentage (4/5) of flaps were salvaged. One flap lap loss occurred in a patient with hyperhomocysteinemia.
CONCLUSIONS:
Although recent efforts are growing, consensus microsurgical guidelines for prophylactic anticoagulation are lacking and studies are limited. One promising effort comes from the Enhanced Recovery after Surgery Society. 3 The limited plastic surgery evidence suggests that it is useful to assess practices of other disciplines, including orthopedics. We achieved FTT outcomes free of postdischarge VTEs and hematomas by routinely prescribing oral factor Xa inhibitors. Novel to microsurgery, this regiment has been strongly validated in orthopedic surgery. Large multicenter orthopedic studies like the RECORD and XA-MOS studies and ORTHO-TEP registry have proven less mortality and bleeding risks with rivaroxaban compared to LMWH, enoxaparin, and fondaparinux. Our study indicates a potential similar efficacy for FTT patients, and further studies should be done to validate these findings.
